Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vivus: into single digits -- Ignore unavailable to you. Want to Upgrade?

To: MIKE DUBIS who wrote (587)	6/15/1998 11:40:00 PM
From: Bradpalm1	Read Replies (2) \| Respond to of 1016

Mike, I no longer follow Vivus to the degree required to answer your questions. Declining 'script numbers is only part of the problem. This company is fatally flawed and is heading down to zero (IMO). Bradpalm1

To: MIKE DUBIS who wrote (587)	6/16/1998 12:39:00 AM
From: VLAD	Read Replies (1) \| Respond to of 1016

MIKE, Don't get too smug and let your head swell. I don't have a lot of time right now for debate but heres a few quick answers for you. 1)The patent is for 7 years (I stand corrected). 2)MUSE has a 18 month shelf life and as of yet none of the product has been returned to Vivus. Individual pharmacies may return product to the wholesalers if they wish and the product can then be redistributed to another pharmacy. 3)I or someone else will (I don't have time tonight) post an article on how and where the IMS compiles the script data--there are a lot of other channels for MUSE sales in the USA that are not accounted for by the IMS. PS The sky is not falling. Many of the points made by myself and others will eventually catch up with Vivus's stock price. The shorts are having a field day. Soon Janssen or Astra will have enough with the shorters and fix your wagon for saying their baby is ugly. It will be sudden and unexpected and you shorts will wonder what hit you.